Published in Blood on December 02, 2004
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet (2006) 2.99
A transposon and transposase system for human application. Mol Ther (2010) 2.28
Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc (2007) 1.73
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A (2005) 1.72
Comparative analysis of transposable element vector systems in human cells. Mol Ther (2010) 1.66
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J (2009) 1.43
Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays (2010) 1.42
Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med (2007) 1.33
Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther (2009) 1.26
DNA transposons: nature and applications in genomics. Curr Genomics (2010) 1.25
PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer. Mol Ther (2009) 1.23
The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet (2011) 1.18
Enzymatic engineering of the porcine genome with transposons and recombinases. BMC Biotechnol (2007) 1.14
Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest (2009) 1.11
The expanding universe of transposon technologies for gene and cell engineering. Mob DNA (2010) 1.08
Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy. Genome Biol (2007) 1.08
Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther (2011) 1.08
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Shielding of sleeping beauty DNA transposon-delivered transgene cassettes by heterologous insulators in early embryonal cells. Mol Ther (2008) 1.02
Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res (2013) 1.01
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
Pigs taking wing with transposons and recombinases. Genome Biol (2007) 0.94
Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy. Mol Ther (2014) 0.93
Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. Hum Gene Ther (2010) 0.92
Retargeting transposon insertions by the adeno-associated virus Rep protein. Nucleic Acids Res (2012) 0.92
Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol (2006) 0.92
Tumor-directed gene therapy in mice using a composite nonviral gene delivery system consisting of the piggyBac transposon and polyethylenimine. BMC Cancer (2009) 0.91
Passport, a native Tc1 transposon from flatfish, is functionally active in vertebrate cells. Nucleic Acids Res (2009) 0.91
Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med (2015) 0.90
Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer (2011) 0.89
Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. PLoS One (2014) 0.89
DNA transposon-based gene vehicles - scenes from an evolutionary drive. J Biomed Sci (2013) 0.89
Cellular immune response against firefly luciferase after sleeping beauty-mediated gene transfer in vivo. Hum Gene Ther (2014) 0.86
Advancements in gene transfer-based therapy for hemophilia A. Expert Rev Hematol (2009) 0.83
piggyBac-mediated phenotypic correction of factor VIII deficiency. Mol Ther Methods Clin Dev (2014) 0.82
Efficient sleeping beauty DNA transposition from DNA minicircles. Mol Ther Nucleic Acids (2013) 0.79
Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery. Mol Ther (2015) 0.79
Efficient non-viral integration and stable gene expression in multipotent adult progenitor cells. Stem Cells Int (2011) 0.78
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med (2016) 0.78
Quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) method for monitoring highly conserved transgene expression during gene therapy. Transl Res (2008) 0.78
Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A. J Genet Syndr Gene Ther (2011) 0.77
Transgene Expression in Dogs after Liver-Directed Hydrodynamic Delivery of <i>Sleeping Beauty</i> Transposons Using Balloon Catheters. Hum Gene Ther (2017) 0.76
A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase. Mol Ther Nucleic Acids (2016) 0.76
Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers. Cancer Biol Ther (2015) 0.76
Prolonged expression of secreted enzymes in dogs after liver-directed delivery of <i>Sleeping Beauty</i> transposons: implications for non-viral gene therapy of systemic disease. Hum Gene Ther (2017) 0.76
Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. Hum Gene Ther (2015) 0.75
Restoration of dystrophin expression using the Sleeping Beauty transposon. PLoS Curr (2011) 0.75
Sleeping Beauty-Mediated Drug Resistance Gene Transfer in Human Hematopoietic Progenitor Cells. Hum Gene Ther (2015) 0.75
Preclinical and clinical advances in transposon-based gene therapy. Biosci Rep (2017) 0.75
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
In vivo genome editing using a high-efficiency TALEN system. Nature (2012) 7.11
Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature (2005) 6.40
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature (2005) 6.20
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther (2003) 3.34
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Harnessing a high cargo-capacity transposon for genetic applications in vertebrates. PLoS Genet (2006) 2.99
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
A primer for morpholino use in zebrafish. Zebrafish (2009) 2.60
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res (2008) 2.57
Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol (2002) 2.30
Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res (2012) 2.29
A transposon and transposase system for human application. Mol Ther (2010) 2.28
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Efficient nonmeiotic allele introgression in livestock using custom endonucleases. Proc Natl Acad Sci U S A (2013) 2.22
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood (2009) 2.15
Mammalian germ-line transgenesis by transposition. Proc Natl Acad Sci U S A (2002) 2.13
Efficient gene delivery and gene expression in zebrafish using the Sleeping Beauty transposon. Dev Biol (2003) 2.01
Transposon mutagenesis of the mouse germline. Genetics (2003) 2.00
RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther (2005) 1.98
Sickle cell trait and the risk of venous thromboembolism among blacks. Blood (2007) 1.95
A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res (2009) 1.86
Gene mutations and genomic rearrangements in the mouse as a result of transposon mobilization from chromosomal concatemers. PLoS Genet (2006) 1.84
Target-site preferences of Sleeping Beauty transposons. J Mol Biol (2004) 1.83
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood (2004) 1.82
Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc (2007) 1.73
Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A (2005) 1.72
Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program (2007) 1.65
Moesin1 and Ve-cadherin are required in endothelial cells during in vivo tubulogenesis. Development (2010) 1.64
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet (2013) 1.60
Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet (2005) 1.60
D-dimer antigen: current concepts and future prospects. Blood (2008) 1.59
Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol (2004) 1.58
Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery. Mol Ther (2010) 1.57
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood (2014) 1.53
Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability. Blood (2012) 1.51
De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res (2009) 1.49
Structure-based prediction of insertion-site preferences of transposons into chromosomes. Nucleic Acids Res (2006) 1.48
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A (2007) 1.48
Nicotine response genetics in the zebrafish. Proc Natl Acad Sci U S A (2009) 1.45
Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther (2004) 1.44
Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells (2007) 1.44
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res (2009) 1.43
Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg (2013) 1.43
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood (2011) 1.43
Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays (2010) 1.42
Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood (2005) 1.40
Precision editing of large animal genomes. Adv Genet (2012) 1.34
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res (2009) 1.34
Expression of VE-cadherin in zebrafish embryos: a new tool to evaluate vascular development. Dev Dyn (2004) 1.34
Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med (2007) 1.33
Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol Ther (2003) 1.31
Excision of Sleeping Beauty transposons: parameters and applications to gene therapy. J Gene Med (2004) 1.30
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther (2012) 1.29
Mojo Hand, a TALEN design tool for genome editing applications. BMC Bioinformatics (2013) 1.29
Hopping around the tumor genome: transposons for cancer gene discovery. Cancer Res (2005) 1.28
SCORE imaging: specimen in a corrected optical rotational enclosure. Zebrafish (2010) 1.26
Blood coagulation: hemostasis and thrombin regulation. Anesth Analg (2009) 1.24
Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther (2009) 1.24
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Mol Ther (2005) 1.23
Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res (2009) 1.22
Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther (2007) 1.21
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet (2011) 1.18